Filing identity and reporting period
Important discrepancy: The request identifies Lite Strategy, Inc. and 2020 Q3, but the supplied filing is for MEI Pharma, Inc., a clinical-stage pharmaceutical company. It is a Form 10-Q for the three and nine months ended March 31, 2022 (MEI’s fiscal third quarter), filed May 23, 2022. The financial statements are unaudited; 2021 comparative results are restated.
MEI’s pipeline comprises zandelisib, voruciclib and ME-344. Revenue is primarily from its collaboration and license arrangements, notably with Kyowa Kirin Company (KKC); the business remains focused on clinical development rather than marketed products.
Financial results and position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | 2022: $9.7 million; 2021: $8.1 million | 2022: $29.3 million; 2021: $27.3 million |
| Research and development | 2022: $22.3 million; 2021: $17.9 million | 2022: $63.8 million; 2021: $53.1 million |
| General and administrative | 2022: $8.9 million; 2021: $6.2 million | 2022: $24.8 million; 2021: $17.8 million |
| Operating loss | 2022: $21.6 million; 2021: $16.4 million | 2022: $59.3 million; 2021: $45.0 million |
| Net loss | 2022: $8.7 million; 2021: $25.6 million | 2022: $38.4 million; 2021: $32.9 million |
| Basic loss per share | 2022: $0.07; 2021: $0.23 | 2022: $0.32; 2021: $0.29 |
Revenue increased year over year, largely reflecting KKC-related development activity and reimbursements. Operating expenses grew faster than revenue, widening the operating loss. The lower quarterly net loss chiefly reflects a non-cash $12.8 million gain from remeasuring warrant liabilities; the nine-month non-cash gain was $20.8 million. These gains are not operating cash inflows. Gross margin is not a useful indicator here: 2022 cost of revenue was reported as zero, while the company’s principal costs were research and development and general and administrative expenses.
For the nine months, operating cash use was $33.2 million, versus $20.7 million in the restated prior-year period. Investing activities used $13.2 million, mainly net purchases of short-term investments; financing provided $49.0 million, including $48.7 million net proceeds from a December 2021 stock offering. Cash and cash equivalents were $11.1 million at March 31, 2022, and short-term investments were $157.9 million, for combined liquidity of $169.0 million.
Total assets were $194.4 million and stockholders’ equity was $67.8 million. The filing reports no conventional borrowings. Liabilities included $10.0 million of operating lease obligations, $96.7 million of deferred revenue under the KKC agreement, and a $1.5 million warrant liability. MEI stated that available resources were expected to fund obligations and operations for at least 12 months from issuance, while warning that it expects continuing operating losses, negative operating cash flow and increased R&D spending.
Material changes, restatement and unusual items
- Revenue and R&D increased year over year; nine-month G&A also rose materially, partly due to higher personnel, professional services, legal and corporate costs.
- MEI restated 2021 interim results for errors in revenue recognition under the KKC agreement, including the timing and allocation of revenue using the cost-to-cost method. For the nine months ended March 31, 2021, revenue was restated upward by $11.9 million and net loss reduced by the same amount to $32.9 million. The restatement did not change operating expenses or cash and short-term investments. The filing says the cumulative effect at December 31, 2021 was a $3.9 million misstatement of deferred revenue and accumulated deficit.
- Management identified a material weakness in internal control over financial reporting related to accounting for license-agreement revenue and concluded internal controls and disclosure controls were ineffective as of March 31, 2022. Remediation was planned but not yet completed.
- Shares outstanding rose from 112.6 million at June 30, 2021 to 133.2 million at March 31, 2022, principally reflecting the December offering. The company also had 16.1 million outstanding warrants exercisable at $2.54 per share and expiring May 2023.
Outlook, management commentary and risks
- Zandelisib: The FDA advised that randomized trials are needed to assess PI3K inhibitor efficacy and safety and discouraged an application based on the single-arm Phase 2 TIDAL study. MEI therefore no longer planned to seek FDA approval using TIDAL alone and was continuing the randomized Phase 3 COASTAL trial. FDA also recommended further dose exploration. The filing described COASTAL as intended to support U.S. and global applications.
- Russia and Ukraine trial sites for COASTAL were suspended because of the military conflict and required replacement; management warned that recruitment timelines could be affected. COVID-19 had also negatively affected enrollment rates in certain studies and could disrupt trials, manufacturing, supplies or regulatory timelines.
- Management expected continued operating losses and negative operating cash flow, with R&D expenses likely to increase. MEI may need future equity or debt financing, license transactions or partnerships; its ability to raise capital on acceptable terms is not assured.
- MEI received a Nasdaq notice on May 9, 2022 for failing the $1.00 minimum bid-price requirement. The initial compliance period ran through November 7, 2022; the filing said compliance had not been regained when the statements were issued. Delisting could impair share liquidity and future fundraising.
- Other principal risks include clinical-trial outcomes and delays, regulatory approval, collaborator performance, drug manufacturing and supply, competition, and the possibility that candidates do not prove safe or effective. The filing also reported a January 2022 office lease amendment, bringing total space to approximately 45,100 square feet and stated contractual lease obligations of approximately $21.5 million over the amended term.
Most important facts for investors to verify
- Confirm the issuer and period: the supplied document is MEI Pharma’s quarter ended March 31, 2022, not Lite Strategy’s 2020 Q3 filing.
- Review the restatement’s effects across all affected periods and assess progress on the revenue-recognition control remediation.
- Track cash use, clinical-development spending and financing needs against management’s stated 12-month liquidity outlook.
- Verify COASTAL enrollment and site replacement progress, and assess the consequences of the FDA’s randomized-trial and dose-exploration position for zandelisib.
- Check Nasdaq bid-price compliance and potential dilution from equity issuance, warrants and equity awards.